CAI Q3 2021 Earnings — Caris Life Sciences, Inc. Revenue & Financial Results | Market Cap Arena

CAICaris Life Sciences, Inc.

$5B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$101M+27.5% YoY

Gross Profit

$54M53.6% margin

Operating Income

$66M65.9% margin

Net Income

$51M50.7% margin

EPS (Diluted)

$2.92

QoQ Revenue Growth

+17.7%

Cash Flow

Operating Cash Flow

$98M

Free Cash Flow

-$448M

Stock-Based Comp.

$566,000

Balance Sheet

Total Assets

$3.3B

Total Liabilities

$2.5B

Stockholders' Equity

$801M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$101M	$79M	+27.5%
Gross Profit	$54M	$49M	+11.2%
Operating Income	$66M	$36M	+86.9%
Net Income	$51M	$15M	+231.3%